Chao Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chao Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Lixian Li
Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China
2 shared publicationsWanyi Chen
Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China
2 shared publications- Wanyi Chen
Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China
2 shared publications Xiaogang Hu
Department of Pharmacy, Chongqing Jiulongpo People’s Hospital, Chongqing, China
2 shared publications- Xiaogang Hu
Department of Pharmacy, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
2 shared publications Xiaoxiao Wang
Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China
2 shared publications
Latest Publications
- Open Access
- 26 August 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1645634
Berberine protects against gefitinib-induced liver injury by inhibiting the HMGB1/TLR4/NF-κB pathway
Background: Gefitinib (GEF), a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC), is frequently associated with drug-induced liver injury (DILI), thereby limiting its clinical application. This study aimed to evaluate the hepatoprotective effects of berberine (BBR) and explore the underlying mechanisms.Methods: In vitro, human hepatocyte lines (THLE-2 and THLE-3) were exposed to GEF alone or in combination with HMGB1 siRNA, a TLR4 inhibitor, an NF-κB inhibitor, or varying concentrations of BBR to assess hepatotoxicity and the involvement of the HMGB1/TLR4/NF-κB pathway. In vivo, Sprague-Dawley (SD) rats were treated with GEF with or without different doses of BBR for 21 days. Liver injury and inflammatory responses were assessed, and pathway alterations were evaluated at both transcriptional and protein levels.Results: GEF activated the HMGB1/TLR4/NF-κB pathway in vitro, increasing the levels of p-NF-κB p65, ALT, AST, and pro-inflammatory cytokines (INF-α, IL-1β and IL-6). BBR inhibited these effects in a concentration-dependent manner by suppressing pathway activation, reducing hepatotoxicity, and inhibiting HMGB1 nuclear-to-cytoplasmic translocation. In vivo, GEF induced weight loss, an increased liver-to-body weight ratio, elevated serum transaminases and pro-inflammatory cytokines, and histopathological liver injury, all of which were dose-dependently ameliorated by BBR co-administration. Moreover, BBR significantly downregulated the expression of HMGB1, TLR4, and NF-κB at both mRNA and protein levels in liver tissues.Conclusion: GEF-induced liver injury is mediated by HMGB1-driven inflammation via the TLR4/NF-κB pathway. BBR provides dose-dependent hepatoprotection by targeting this pathway, suggesting a potential strategy to protect against GEF-induced liver injury among NSCLC patients.
- 26 August 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1645634
Open AccessBerberine protects against gefitinib-induced liver injury by inhibiting the HMGB1/TLR4/NF-κB pathway
Background: Gefitinib (GEF), a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC), is frequently associated with drug-induced liver injury (DILI), thereby limiting its clinical application. This study aimed to evaluate the hepatoprotective effects of berberine (BBR) and explore the underlying mechanisms.Methods: In vitro, human hepatocyte lines (THLE-2 and THLE-3) were exposed to GEF alone or in combination with HMGB1 siRNA, a TLR4 inhibitor, an NF-κB inhibitor, or varying concentrations of BBR to assess hepatotoxicity and the involvement of the HMGB1/TLR4/NF-κB pathway. In vivo, Sprague-Dawley (SD) rats were treated with GEF with or without different doses of BBR for 21 days. Liver injury and inflammatory responses were assessed, and pathway alterations were evaluated at both transcriptional and protein levels.Results: GEF activated the HMGB1/TLR4/NF-κB pathway in vitro, increasing the levels of p-NF-κB p65, ALT, AST, and pro-inflammatory cytokines (INF-α, IL-1β and IL-6). BBR inhibited these effects in a concentration-dependent manner by suppressing pathway activation, reducing hepatotoxicity, and inhibiting HMGB1 nuclear-to-cytoplasmic translocation. In vivo, GEF induced weight loss, an increased liver-to-body weight ratio, elevated serum transaminases and pro-inflammatory cytokines, and histopathological liver injury, all of which were dose-dependently ameliorated by BBR co-administration. Moreover, BBR significantly downregulated the expression of HMGB1, TLR4, and NF-κB at both mRNA and protein levels in liver tissues.Conclusion: GEF-induced liver injury is mediated by HMGB1-driven inflammation via the TLR4/NF-κB pathway. BBR provides dose-dependent hepatoprotection by targeting this pathway, suggesting a potential strategy to protect against GEF-induced liver injury among NSCLC patients.
- Open Access
- 21 April 2025
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 47 (4) , 1120
Correction: Developing a machine learning-based predictive model for the analgesic effectiveness of transdermal fentanyl in cancer patients: an interpretable approach
- 21 April 2025
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 47 (4) , 1120
Open AccessCorrection: Developing a machine learning-based predictive model for the analgesic effectiveness of transdermal fentanyl in cancer patients: an interpretable approach
- 11 April 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (3) , 789-799
High BMI predicts poor cancer pain relief when rotating from oral opioids to transdermal Fentanyl: a two-center retrospective study
Background The analgesic effect of transdermal fentanyl (TDF) differs among cancer pain patients. This study aims to investigate the relationship between clinical factors and pain relief when using TDF in cancer pain patients who rotate from oral opioids to TDF. Methods A two-center retrospective study was conducted in Chongqing University Cancer Hospital and Sichuan Cancer Hospital, including adult cancer pain patients who rotated from oral opioids to TDF between 2018 and 2022. Based on the clinical characteristics, logistic regressions and directed acyclic graphs (DAG) were employed to identify significant factors influencing the efficacy of TDF. The study adhered to STROBE guidelines. Results This survey included 359 patients, among them, 254 patients (70.8%) attained good pain relief after rotating to TDF. 59.3% of patients utilized TDF at standard dosage, while 24.8% used underdose TDF, with only 52.8% achieving adequate pain relief, significantly lower than other groups (p < 0.001). Initial univariable analysis of 22 clinical factors among the standard dose group showed that a higher body mass index (BMI, median 23.2 kg/m² vs. 21.0 kg/m², OR = 0.83 [0.75–0.91], p < 0.001) and the presence of lung cancer (OR = 0.31 [0.11–0.89], p = 0.030) predicted potentially unsatisfactory pain control after TDF treatment. Subsequently, a multivariable regression analysis based on DAG-directed factor selection identified BMI (OR = 0.82 [0.74–0.92], adjusted p < 0.01) as the only independent factor influencing TDF effectiveness. Conclusions Our study suggested that high BMI was a significant predictor of poor cancer pain relief when rotating from oral opioids to TDF, and provides a useful measurement of managing adult cancer pain when using TDF. Trial registration ClinicalTrials.gov, NCT06369961, registered on April 11, 2024; https://clinicaltrials.gov/study/NCT06369961.
- 11 April 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (3) , 789-799
High BMI predicts poor cancer pain relief when rotating from oral opioids to transdermal Fentanyl: a two-center retrospective study
Background The analgesic effect of transdermal fentanyl (TDF) differs among cancer pain patients. This study aims to investigate the relationship between clinical factors and pain relief when using TDF in cancer pain patients who rotate from oral opioids to TDF. Methods A two-center retrospective study was conducted in Chongqing University Cancer Hospital and Sichuan Cancer Hospital, including adult cancer pain patients who rotated from oral opioids to TDF between 2018 and 2022. Based on the clinical characteristics, logistic regressions and directed acyclic graphs (DAG) were employed to identify significant factors influencing the efficacy of TDF. The study adhered to STROBE guidelines. Results This survey included 359 patients, among them, 254 patients (70.8%) attained good pain relief after rotating to TDF. 59.3% of patients utilized TDF at standard dosage, while 24.8% used underdose TDF, with only 52.8% achieving adequate pain relief, significantly lower than other groups (p < 0.001). Initial univariable analysis of 22 clinical factors among the standard dose group showed that a higher body mass index (BMI, median 23.2 kg/m² vs. 21.0 kg/m², OR = 0.83 [0.75–0.91], p < 0.001) and the presence of lung cancer (OR = 0.31 [0.11–0.89], p = 0.030) predicted potentially unsatisfactory pain control after TDF treatment. Subsequently, a multivariable regression analysis based on DAG-directed factor selection identified BMI (OR = 0.82 [0.74–0.92], adjusted p < 0.01) as the only independent factor influencing TDF effectiveness. Conclusions Our study suggested that high BMI was a significant predictor of poor cancer pain relief when rotating from oral opioids to TDF, and provides a useful measurement of managing adult cancer pain when using TDF. Trial registration ClinicalTrials.gov, NCT06369961, registered on April 11, 2024; https://clinicaltrials.gov/study/NCT06369961.
- 17 March 2025
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 47 (4) , 1011-1023
Developing a machine learning-based predictive model for the analgesic effectiveness of transdermal fentanyl in cancer patients: an interpretable approach
Background Cancer-related pain is a common and distressing symptom in patients with malignant tumors, significantly affecting quality of life. Transdermal fentanyl is a convenient opioid option for patients with intestinal obstruction or difficulty swallowing; however, some patients do not experience adequate pain relief. Predicting transdermal fentanyl analgesic effectiveness is crucial to optimize pain management. Aim This study aimed to develop a predictive model for transdermal fentanyl effectiveness in cancer patients. Method Clinical data from adult cancer pain patients at Chongqing University Cancer Hospital were analyzed (January 2020—December 2022). Logistic regression and feature selection were applied, followed by developing nine predictive models using Logistic Regression, Random Forest (RF), and Extreme Gradient Boosting. The receiver operating characteristic (ROC) curves, the Youden index, and the Brier score were used to evaluate the performance of the model. Cross-validation and SHapley Additive exPlanations (SHAP) analysis were used for validation and feature interpretation. Results Among 151 patients, 27.2% reported ineffectiveness of transdermal fentanyl. Logistic regression identified key factors of NRS, transdermal fentanyl dosage, BMI2, and ALT. Among the nine models, RF Model 8 exhibited the best performance, achieving a ROC-AUC of 0.984 (95% CI: [0.968, 0.999]). This performance was further validated by the confusion matrix metrics and visualization results. The SHAP analysis highlighted lower doses, NRS, and ALT as predictors of transdermal fentanyl ineffectiveness. Conclusion The Random Forest model offers a valuable tool for predicting the effectiveness of transdermal fentanyl in cancer pain patients, supporting the refined assessment and management of pain.
- 17 March 2025
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 47 (4) , 1011-1023
Developing a machine learning-based predictive model for the analgesic effectiveness of transdermal fentanyl in cancer patients: an interpretable approach
Background Cancer-related pain is a common and distressing symptom in patients with malignant tumors, significantly affecting quality of life. Transdermal fentanyl is a convenient opioid option for patients with intestinal obstruction or difficulty swallowing; however, some patients do not experience adequate pain relief. Predicting transdermal fentanyl analgesic effectiveness is crucial to optimize pain management. Aim This study aimed to develop a predictive model for transdermal fentanyl effectiveness in cancer patients. Method Clinical data from adult cancer pain patients at Chongqing University Cancer Hospital were analyzed (January 2020—December 2022). Logistic regression and feature selection were applied, followed by developing nine predictive models using Logistic Regression, Random Forest (RF), and Extreme Gradient Boosting. The receiver operating characteristic (ROC) curves, the Youden index, and the Brier score were used to evaluate the performance of the model. Cross-validation and SHapley Additive exPlanations (SHAP) analysis were used for validation and feature interpretation. Results Among 151 patients, 27.2% reported ineffectiveness of transdermal fentanyl. Logistic regression identified key factors of NRS, transdermal fentanyl dosage, BMI2, and ALT. Among the nine models, RF Model 8 exhibited the best performance, achieving a ROC-AUC of 0.984 (95% CI: [0.968, 0.999]). This performance was further validated by the confusion matrix metrics and visualization results. The SHAP analysis highlighted lower doses, NRS, and ALT as predictors of transdermal fentanyl ineffectiveness. Conclusion The Random Forest model offers a valuable tool for predicting the effectiveness of transdermal fentanyl in cancer pain patients, supporting the refined assessment and management of pain.
- 7 February 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 110 (2) , 274-278
Case Report: Successful Treatment of Cerebral Phaeohyphomycosis with Voriconazole: A Case Report and Literature Review
: Fonsecaea monophora is a species of Fonsecaea that belongs to Chaetothyriales. It is usually isolated from tropical and subtropical regions, causing reactive inflammation, skin abscesses, and pain. Cerebral infection caused by F. monophora is rare but often fatal. Diagnosing this disease at an early stage is difficult, and appropriate antifungal therapy is often delayed as a result. We report the case of a 53-year-old woman with type 2 diabetes who presented with a headache 2 months ago and progressive right-sided weakness of 1 month’s duration. Magnetic resonance imaging revealed a space-occupying lesion in the left frontal lobe and corpus callosum. The cystic mass was removed by surgical intervention, and the identification of the sample based on sequencing of the internal transcribed spaced region in BLAST-N search showed that the sequences producing most significant alignments were F. monophora or similar (query cover 99%, E value 0.0, per ident 99.84). The patient was treated with a 3-month course of twice daily voriconazole, leading to complete recovery.
- 7 February 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 110 (2) , 274-278
Case Report: Successful Treatment of Cerebral Phaeohyphomycosis with Voriconazole: A Case Report and Literature Review
: Fonsecaea monophora is a species of Fonsecaea that belongs to Chaetothyriales. It is usually isolated from tropical and subtropical regions, causing reactive inflammation, skin abscesses, and pain. Cerebral infection caused by F. monophora is rare but often fatal. Diagnosing this disease at an early stage is difficult, and appropriate antifungal therapy is often delayed as a result. We report the case of a 53-year-old woman with type 2 diabetes who presented with a headache 2 months ago and progressive right-sided weakness of 1 month’s duration. Magnetic resonance imaging revealed a space-occupying lesion in the left frontal lobe and corpus callosum. The cystic mass was removed by surgical intervention, and the identification of the sample based on sequencing of the internal transcribed spaced region in BLAST-N search showed that the sequences producing most significant alignments were F. monophora or similar (query cover 99%, E value 0.0, per ident 99.84). The patient was treated with a 3-month course of twice daily voriconazole, leading to complete recovery.
- Open Access
- 22 June 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (7) , 1321
Stimuli-Responsive Gold Nanocages for Cancer Diagnosis and Treatment
With advances in nanotechnology, various new drug delivery systems (DDSs) have emerged and played a key role in the diagnosis and treatment of cancers. Over the last two decades, gold nanocages (AuNCs) have been attracting considerable attention because of their outstanding properties. This review summarizes current advancements in endogenous, exogenous, and dual/multi-stimuli responsive AuNCs in drug delivery. This review focuses on the properties, clinical translation potential, and limitations of stimuli-responsive AuNCs for cancer diagnosis and treatment.
- 22 June 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (7) , 1321
Open AccessStimuli-Responsive Gold Nanocages for Cancer Diagnosis and Treatment
With advances in nanotechnology, various new drug delivery systems (DDSs) have emerged and played a key role in the diagnosis and treatment of cancers. Over the last two decades, gold nanocages (AuNCs) have been attracting considerable attention because of their outstanding properties. This review summarizes current advancements in endogenous, exogenous, and dual/multi-stimuli responsive AuNCs in drug delivery. This review focuses on the properties, clinical translation potential, and limitations of stimuli-responsive AuNCs for cancer diagnosis and treatment.
- Open Access
Diastereodivergent and Enantioselective [4+2] Annulations of γ-Butenolides with Cyclic 1-Azadienes
An asymmetric annulation reaction of γ-butenolides and cyclic 1-azadienes containing a 1,2-benzoisothiazole-1,1-dioxide motif has been studied, proceeding in a tandem Michael addition-aza-Michael addition sequence. Endo-type cycloadducts bearing fused tetracyclic skeletons were isolated in fair yields and with high enantioselectivity (up to >99% ee) under the catalysis of modified cinchona alkaloid (DHQD)2PHAL. Besides, exo-type diastereomers could be produced using β-isocupreidine (β-ICD) as the catalyst, though with moderate enantioselectivity.
Open AccessDiastereodivergent and Enantioselective [4+2] Annulations of γ-Butenolides with Cyclic 1-Azadienes
An asymmetric annulation reaction of γ-butenolides and cyclic 1-azadienes containing a 1,2-benzoisothiazole-1,1-dioxide motif has been studied, proceeding in a tandem Michael addition-aza-Michael addition sequence. Endo-type cycloadducts bearing fused tetracyclic skeletons were isolated in fair yields and with high enantioselectivity (up to >99% ee) under the catalysis of modified cinchona alkaloid (DHQD)2PHAL. Besides, exo-type diastereomers could be produced using β-isocupreidine (β-ICD) as the catalyst, though with moderate enantioselectivity.